期刊
ANNALS OF NEUROLOGY
卷 90, 期 4, 页码 683-690出版社
WILEY
DOI: 10.1002/ana.26189
关键词
-
资金
- NHMRC [APP1141169]
- Wellcome Trust [104079/Z/14/Z]
- Medical Research Council [MR/V007173/1]
- MRC [MR/V003534/1] Funding Source: UKRI
Pain is an under-recognized association of LGI1 and CASPR2 antibodies, with CASPR2 antibody patients experiencing pain at a higher rate (52%) compared to LGI1 antibody patients (19%). Pain in LGI1 antibody patients responded well to immunotherapy, while CASPR2 antibody patients showed greater residual impairment. Serum CASPR2 antibodies, but not LGI1 antibodies, bound to sensory neurons, indicating potential pathophysiological differences underlying clinical observations.
Pain is a under-recognized association of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies. Of 147 patients with these autoantibodies, pain was experienced by 17 of 33 (52%) with CASPR2- versus 20 of 108 (19%) with LGI1 antibodies (p = 0.0005), and identified as neuropathic in 89% versus 58% of these, respectively. Typically, in both cohorts, normal nerve conduction studies and reduced intraepidermal nerve fiber densities were observed in the sampled patient subsets. In LGI1 antibody patients, pain responded to immunotherapy (p = 0.008), often rapidly, with greater residual patient-rated impairment observed in CASPR2 antibody patients (p = 0.019). Serum CASPR2 antibodies, but not LGI1 antibodies, bound in vitro to unmyelinated human sensory neurons and rodent dorsal root ganglia, suggesting pathophysiological differences that may underlie our clinical observations. ANN NEUROL 2021
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据